STAT6 and neoplasm: These concepts can serve as a foundation for future studies incorporating biomarkers such as NAB2-STAT6 fusion transcript types into the risk assessment model and also for the establishment of targeted therapy (since the tumor harbors a particular fusion product), especially in malignant cases.